• Tempus AI announced study results showing its AI-enabled pre-screening panel could help identify advanced non-small cell lung cancer patients needing biomarker testing.
• The analysis covered 60,459 cases across 56,969 patients through a collaboration with Pfizer.
• Results were presented at the European Society for Medical Oncology Congress 2026 in Madrid.
• The panel analyzes routine pathology images to help prioritize diagnostic testing, potentially accelerating treatment decisions while preserving limited tumor tissue.
• The panel remains in development as a tool to guide subsequent testing, not replace established molecular or immunohistochemistry tests.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261019198806) on October 19, 2026, and is solely responsible for the information contained therein.